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The steady-state pharmacokinetics of cefepime

were

evaluated in 10 middle-aged and elderly patients with

acute lower respiratory tract infections who were receiving 1 g intravenously every 12 h. One preinfusion and
15 postinfusion serum samples and total urine output were collected over one dosing interval between days 3
and 8 of therapy. Cefepime concentrations in serum over time exhibited a multicompartmental profile. Peak

and trough concentrations in serum determined by a validated high-performance liquid chromatography
method were 71.2 ± 17.2 (mean ± standard deviation) and 6.0 ± 4.9 mg/liter, respectively. The steady-state
volume of distribution was 0.22 ± 0.05 liter/kg. Elimination half-lives ranged from 1.93 to 6.04 h (3.92 ± 1.28
h), and total body clearances ranged from 36.9 to 102 ml/min per 1.73 m2 (73.0 ± 19.7 ml/min per 1.73 m2).
The disposition of cefepime at steady state in patients was comparable to previous observations in healthy
elderly volunteers. The predictive performance of regression equations derived from single-dose studies in
volunteers relating creatinine clearance with total body and renal clearances of cefepime exhibited slight biases
(mean predictive errors, -9.7 and 2.1 ml/min per 1.73 m2, respectively) and similar precisions. Predicted and
observed total body clearances (63.3 ± 25.1 versus 73.0 ± 19.7 ml/min per 1.73 m2, respectively) and renal
clearances (51.3 ± 24.4 versus 49.3 ± 19.6 ml/min per 1.73 m2, respectively) were not significantly different.
The pharmacokinetics of cefepime in infected patients appeared to be unaltered by illness, and the steady-state
disposition of cefepime was predictable from data derived from single-dose studies in volunteers.

Cefepime is an investigational cephalosporin which, in
comparison with currently marketed extended-spectrum
agents, demonstrates increased coverage against gram-positive organisms while retaining a broad spectrum of activity
against gram-negative organisms. Against members of the
family Enterobacteriaceae, MICs for 90% of strains are
generally <0.5 mg/liter, against Pseudomonas aeruginosa
they are <8 mg/liter, and against Staphylococcus aureus
they are <4 mg/liter (6, 15, 16). In healthy adult volunteers,
cefepime exhibited a multicompartmental serum concentration-versus-time profile with an elimination half-life (t12,3) of
approximately 2 h (14). The pharmacokinetic disposition of
cefepime has also been characterized in healthy elderly
volunteers after single-dose intravenous administration. Elderly subjects had higher concentrations of drug in serum
throughout the sampling period, with a prolonged t1/2,3 and
decreased systemic clearance primarily because of agerelated decreases in renal function (R. H. Barbhaiya, C. A.
Knupp, K. A. Pittman, J. Tenny, and R. R. Martin, Proc.
16th Int. Congr. Chemother., p. 307, 1989). Consistent with
the fact that renal clearance (CLR) represents the primary
route of cefepime elimination, creatinine clearance (CLCR),
systemic cefepime clearance (CL), and CLR are highly
correlated (S. T. Forgue, D. R. P. Guay, E. A. Morgenthein,
G. R. Matzke, and R. H. Barbhaiya, Program Abstr. 28th
Intersci. Conf. Antimicrob. Agents Chemother., abstr. no.
129, 1988).
While those investigations involved noninfected volunteers who were evaluated following single-dose administra*

tion, the ultimate recipients of an intravenous antibiotic are
hospitalized patients who receive maintenance-dose therapy
for the treatment of infections. Pharmacokinetic parameters
derived from single-dose studies, however, do not always
accurately predict multiple-dose disposition (8). Moreover,
the presence of an acute infection itself has been identified
by some investigators as a factor which can significantly
alter the pharmacokinetics of antibiotics (5, 7, 12). Such an
effect has not, however, been consistently observed (3,
9-11). Inasmuch as the pharmacokinetics of cefepime have
not been evaluated during maintenance-dose administration
in older subjects or in patients with acute illnesses, this study
was designed to characterize its disposition at steady state in
middle-aged and elderly hospitalized patients being treated
for respiratory tract infections. Furthermore, the accuracy
with which the steady-state pharmacokinetics of cefepime in
patients could be predicted from the relationships between
CLCR and cefepime CL and CLR derived from studies in
noninfected volunteers was assessed.

MATERIALS AND METHODS
Patients. Patients who were moderately to severely ill with
lower respiratory tract infections were enrolled in the study.
Subjects were excluded if they had a known allergy to
cephalosporins or had impairment of renal function (serum
creatinine level, >2.1 mg/dl) or hepatic function (alanine
aminotransferase, aspartate aminotransferase, or bilirubin
greater than twice the upper limit of normal). All patients
received cefepime under a clinical efficacy and safety investigational protocol approved by the Medical Ethics Committees of the University Hospital Utrecht and the Lichtenberg
Hospital, Amersfoort, The Netherlands. Informed consent
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2.0 ml/min. Retention times of cefepime and internal standard in the serum assay were 8.2 and 20 min, respectively,
and in the urine assay they were 12 and 15 min, respectively.
The minimum detectable concentration was 0.5 mg/liter in
serum and 2.5 mg/liter in urine. No chromatographic interference from theophylline and a variety of other drugs was
observed. The intra- and interassay coefficients of variation
were less than 14% for low (1 mg/liter) and 4% for high (50
mg/liter) cefepime standards in serum and less than 11% for
low (10 mg/liter) and 3% for high (500 mg/liter) cefepime
standards in urine which were prepared in our laboratory.
Data analysis. The elimination rate constant (,B) of the
log-linear terminal portion of the cefepime serum concentration-versus-time curve (times, 5 to 11.5 h after the infusion)
was determined by nonlinear regression anaiysis with
weighting of 1/y2. tl/2,1 was calculated as ln 2/p. CL, CLR,
and volume of distribution at steady state (Vss) were calculated from the following equations: CL = dose/AUC; CLR =
(A)(V)/AUC; and Vss = (MRT - T/2) CL. In these equations,
dose is the intravenous cefepime administered; AUC is the
area under the concentration-time curve over the dosing
interval from 0 to 12 h at steady state obtained by the
trapezoidal rule; A is the concentration of cefepime excreted
unchanged in urine; V is the volume of urine, and T is
infusion duration. Mean residence time (MRT) was calculated by the method of Bauer and Gibaldi (2), and nonrenal
clearance (CLNR) was determined as the difference between
CL and CLR.
The predictive performance of the relationships between
CLCR and cefepime CL and CLR in noninfected volunteers
(Forgue et al., 28th ICAAC) was assessed. Cefepime clearances were calculated for each patient by the equations CL
= 0.96 CLCR + 10.92 and CLR = 0.88 CLCR + 0.33, where
CLCR was estimated by the formula of Cockroft and Gualt
(4).
The paired student t test and orthogonal regression analysis were used to compare the observed and predicted
cefepime CLs and CLRs. Mean predictive error was used as
a measure of bias, and root mean squared error was used as
a measure of precision. These were calculated as mean
predictive error = (E pe)ln and root mean squared error =

TABLE 1. Demographic characteristics of study patients
Patient

Wt

CLCR

Infection

36.7

P, B

Ht
Sexa Ae
(cA)
(yr) (kg)
(kg) (cm) (ml/min
Pno.no.
~1.73 M2)per

1

F

62

67.9

152

Relevant medical history"

type'

COPD, diabetes mellitus, chronic
cardiac failure

2

F

79

77.0

163

61.6

B

COPD, hypertension, diverticulosis,

3

M

71

62.9

175

45.4

B

4
S

M
F

60
98

58.0
50.5

176
162

65.2
27.9

B
P

COPD, hypertension, gastritis, arthritis, cardiac decompensation
COPD, atrial hypertrophy
Hypertension, cardiac decompensa-

pyelitis

tion
6

M

74

59.4

163

57.5

P

COPD, diabetes mellitus, intermit-

7
8
9

M
F
M

71
50
89

66.0
84.7
50.8

182
163
178

53.8
120
31.8

P
P
P

tent claudication
Atrial fibrillation, dementia
COPD, atrial fibrillation
COPD, dementia

M
P
10
79 75.0 169
45.5
a F, Female; M, male.
b
CLCR estimated by the formula of Cockroft and Gault (4).
c P, Pneumonia; B, acute exacerbation of chronic bronchitis.
d COPD, Chronic obstructive pulmonary disease.

Lung carcinoma

Concomitant medications

Theophylline, prednisone, insulin,
furosemide, captopril

Theophylline, prednisone, furosemide, temazepam

Theophylline, prednisone, enalapril,
triamterene, amiloride

Furosemide

Theophylline, digoxin, furosemide,
hydralazine, hydrocortisone
Theophylline, prednisone, insulin,
furosemide, digoxin
Haloperidol, trimeprazine
Prednisone

Theophylline, furosemide, flecainide, nitrazepam
Dipyridamole
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granted by the patients or their legal guardians prior to
enrollment in the study.
Study design. A medical history, physical examination,
and laboratory screening profile (hematology, serum chemistry, and urinalysis) were completed for each patient before
participation in the study, on the day of the pharmacokinetic
assessment, and after the conclusion of therapy.
Cefepime was supplied by Bristol-Myers Co., Brussels,
Belgium. Each subject received 1 g of cefepime diluted in
0.9% sodium chloride and infused into a forearm vein over a
30-min period every 12 h. On one occasion between days 3
and 8 of therapy (day 5.5 1.7), multiple blood samples (5
ml) were collected via an indwelling heparin catheter located
in a forearm vein of the arm contralateral to that used for
drug administration. Samples were withdrawn into siliconized glass tubes without additives (Becton Deckinson
Vacutainer Systems, Rutherford, N.J.) prior to administration; 10, 20, and 30 min during infusion; and 5, 15, 30, and 45
min and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 11.5 h after the end of
the infusion. Blood was allowed to clot at room temperature,
and serum was separated by centrifugation and frozen at
-20°C until it was assayed. Urine was collected prior to and
at intervals of 0 to 2, 2 to 4, 4 to 8, and 8 to 12 h after the
beginning of the infusion. After quantitation, a portion of
each urine collection was stored at -20°C until it was
assayed.
Chemical analysis. The concentration of cefepime in serum
and urine was determined by a reverse-phase high-performance liquid chromatographic assay modified fromn Barbhaiya et al. (1). Separation of cefepime from cefadroxil
(serum internal standard) or cephradine (urine internal standard) was achieved by using a C18 reversed-phase column
(LiChroCART 250-4; particle size, 5 ,um; 4.0 by 250 mm; E.
Merck AG, Darmstadt, Federal Republic of Germany) and
UV detection (254-nm wavelength for the serum assay,
280-nm wavelength for the urine assay). The serum mobile
phase consisted of acetonitrile-0.005 M octane sulfonic acid
(14:86) at a flow rate of 1.0 ml/min. The composition of the
urine mobile phase was methanol-0.01 M sodium dodecyl
sulfate-5% (wt/vol) trichloroacetic acid-0.85 M phosphoric
acid-tetrahydrofuran (49.7:40.4:9:0.7:5.3) at a flow rate of
was
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FIG. 1. Serum concentration-time curve (U) and urinary excretion (histogram) of cefepime in patients (n = 10) during maintenance
dose intravenous administration. Data are means + standard deviations.

V/[I.(pe2)/n], where pe = predicted clearance - observed
clearance and n is the number of paired clearances. Statistical significance was assumed at P < 0.05. Data are presented as mean + standard deviation.
RESULTS
The demographic characteristics of study participants are
documented in Table 1. Subjects ranged in age from 50 to 98
14 years) and had a mean weight of
years (mean age, 73
65.2 11.2 kg. Patients were hospitalized with moderate to
severe lower respiratory tract infections, including pneumonia and acute exacerbation of chronic bronchitis. The maximum temperature was 37.9 1.1°C, and the mean prether5.4) x 103/mm3. The
apy leukocyte count was (11.3
duration of cefepime therapy was 10 2 days and was well
tolerated by all subjects. No adverse events or laboratory
abnormalities attributed to the drug were observed. An
episode of mild phlebitis at the site of infusion after 7 days of
therapy occurred in one patient.
A semilogarithmic plot of the cefepime serum concentration-versus-time data was multicompartmental for all patients (Fig. 1). The corresponding pharmacokinetic parameters are displayed in Table 2. Following a 1-g dose, the mean
peak cefepime concentration in serum at the end of the
infusion was 71.2 + 17.2 mg/liter, and the mean trough
concentration 11.5 h after the end of the infusion was 6.0
4.9 mg/liter. t /2 ranged from 1.93 to 6.04 h (3.92 1.28 h),
0.05
and V,. ranged from 0.15 to 0.29 liter/kg (0.22
±

±

±

±

±

±

±

liter/kg). Mean CL, CLR, and CLNR were 73.0 + 19.7, 49.3
+ 19.6, and 24.0 + 8.84 mllmin per 1.73 m2, respectively.
Over the 12-h dosing interval, 65.3% + 14.9% of the dose
was excreted unchanged in the urine. The mean amount of
cefepime excreted during each period of the fractional urine
collection is shown in Fig. 1.
The clearance regression equations exhibited minor mean
predictive errors of -9.7 and 2.1 mllmin per 1.73 m2 for CL
and CLR, respectively, and similar root mean squared errors
of 19.5 and 17.3 ml/min per 1.73 m2, respectively. No
significant differences were noted between mean predicted
and observed CLs (63.3 + 25.1 versus 73.0 + 19.7 mllmin
per 1.73 m2, respectively) or CLRs (51.3 + 24.4 versus 49.3
+ 19.6 ml/min per 1.73 m2, respectively). Furthermore,
predicted and observed clearances were significantly correlated: for CL, r = 0.7088 and P < 0.01; for CLR, r = 0.6706
and P < 0.05.
DISCUSSION
The disposition of cefepime in healthy elderly volunteers
has been reported to differ significantly from that in young
adults (Barbhaiya et al., 16th Int. Congr. Chemother.).
Specifically, elderly subjects exhibited larger volumes of
distribution, prolonged tl/2,s, and decreased systemic clearances. These age-related changes in pharmacokinetic parameters were attributed primarily to decreases in renal function
in elderly individuals. In the present investigation, mean
pharmacokinetic parameters evaluated at steady state in
older patients being treated for acute infections compared
favorably with those of elderly, noninfected volunteers. CLs
in female and male patients were 1.18 and 1.09 ml/min per
kg, respectively, compared with 1.21 and 1.11 ml/min per kg
in elderly female and male volunteers, respectively. When
normalized to body weight, volumes of distribution were
identical in female and male patients (0.22 liter/kg) and were
similar to values derived from healthy elderly females (0.24
liter/kg) and males (0.23 liter/kg). While no gender differences in t4/2, were noted in elderly volunteers (3.05 versus
2.92 h in females and males, respectively), male patients
exhibited slightly longer tl/2,s (4.40 + 1.29 h) than those of
female patients (3.19 + 0.98 h). This difference was not
statistically significant but consistent with the lower CLcRs
observed in this group of male patients (49.9 versus 61.6
ml/min per 1.73 m2 for males and females, respectively).
The variance in pharmacokinetic parameters (area under
the concentration-time curve, t/2f,, and clearances) was

TABLE 2. Steady-state pharmacokinetic parameters of cefepime in patientsa
Patient
no.
Patient

1
2
3
4
5
6
7
8
9
10
Mean ± SD

Cmax

(mg/liter)
41.4
61.8
81.3
68.5
89.8
85.1
47.3
89.8
66.2
80.8
71.2 + 17.2

423

AUC

(h)

(mg- hMiter)

3.80
2.92
6.04
4.01
4.10
2.76
3.61
1.93
5.83
4.17
3.92 + 1.28

232
173
208
241
310
208
189
149
480
323
251 ± 97.5

MRT

VSCL
per
(mi/mi
1.73 in2)

(h)

(liter/kg)

4.33
3.30
3.01
3.24
3.97
3.22
3.82
2.17
4.72
3.90
3.57 + 0.73

0.26
0.23
0.21
0.21
0.24
0.24
0.29
0.15
0.19
0.15
0.22 + 0.05

t/2p,

75.3
91.1
78.3
70.0
61.2
84.5
82.5
102
36.9
48.0
73.0 ± 19.7

CLNRper
(ml/min

(mg)

35.4
63.8
61.6
49.3

39.9
27.3
16.7
20.7

470
700
786
705

65.7

18.8

777

69.6
13.8
35.0
49.3 + 19.6

32.4
23.1
13.0
24.0 + 8.84

683
374
730
653 ± 149

CLR

(ml/min per
1.73 in2)

1.73

M2

Ae

a Abbreviations: Cmax, maximum concentration of cefepime in serum;
elimination half-life; AUC, area under the concentration-time curve; MRT, mean
residence time; Vss, volume of distribution at steady state; CL, systemic clearance; CLR, renal clearance; CLNR, nonrenal clearance; Ae, amount of cefepime
excreted unchanged in urine over 12-h dosing interval.
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(16th Int. Congr. Chemother.). Inasmuch as cefepime is
primarily eliminated unchanged in the urine, variability in
renal function most likely represents the primary factor
accounting for the increased kinetic variance that was observed. Similar findings have been reported for other antibiotics in elderly patients (11).
The regression equations relating renal function with
cefepime CL and CLR derived from single-dose studies in
volunteers performed well in predicting steady-state clearances in patients. A small negative bias was observed for the
CL equation, and a slight positive bias was observed for the
CLR equation; both, however, were less than 10 ml/min per
1.73 m 2. The equations demonstrated similar precision of
approximately 20 ml/min per 1.73 M2. These relationships
would therefore be useful in the clinical setting as the basis
for dosage adjustment (13) for patients with impaired renal
function who are receiving cefepime.
The results of this investigation suggest that the pharmacokinetics of cefepime during maintenance-dose therapy in
middle-aged to elderly, hospitalized patients are consistent
with values projected from single-dose investigations. Furthermore, acute illness does not appear to alter the disposition of cefepime significantly. Relationships between renal
function indices and cefepime clearances derived from noninfected volunteers perform well in predicting the cefepime
disposition during multiple-dose administration in infected
patients.
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greater in this patient population than it was in elderly
volunteers. While these patients are representative of those
treated on our pulmonary ward, they were nonetheless
heterogeneous in terms of infection type, severity of infection, and concurrent disease states. A variety of concomitant
medications was administered during the course of cefepime
therapy (Table 1), some of which, such as diuretics, may
influence the disposition of antibiotics. These factors or a
combination of them may have contributed to the observed
variabilities. Additionally, the range of CLcRs measured in
this patient group was broader than those measured in
elderly subjects in the volunteer study of Barbhaiya et al.
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